Roivant Archives -

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to

Pfizer and Roivant launch autoimmune specialist Priovant

https://pharmaphorum.com/news/pfizer-and-roivant-launch-autoimmune-specialist-priovant/

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phil Taylor Dermavant, Immunology and inflammation, psoriasis, Roivant, tapinarof 0 Comment

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

https://pharmaphorum.com/news/phase-3-wins-put-dermavant-closer-to-filing-otezla-rival-tapinarof/

News/ News/ R&D/ Top stories

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

Richard Staines Actemra, coronavirus, COVID-19, infectious diseases, Roche, Roivant 0 Comment

Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with

Roche begins phase 3 trial of Actemra in COVID-19 pneumonia

https://pharmaphorum.com/news/roche-begins-phase-3-trial-of-actemra-in-covid-19-pneumonia/

News/ News/ News/ R&D/ Sales and Marketing/ Top stories

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

Phil Taylor Mergers and acquisitions, Roivant, Sumitomo Dainippon Pharma, Sumitovant Bopharma 0 Comment

A new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant

Sumitomo, Roivant close $3 billion deal, forming Sumitovant

https://pharmaphorum.com/news/sumitomo-roivant-close-3-billion-deal-forming-sumitovant/

News/ News/ R&D

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

Phil Taylor cystic fibrosis, gene therapy, M&A, Roivant, Sumitomo Dainippon Pharma 0 Comment

Six weeks after Sumitomo Dainippon Pharma agreed a $3 billion deal to license a host of drug candidates

Sumitomo and Roivant put flesh on bones of $3bn R&D deal

https://pharmaphorum.com/news/sumitomo-and-roivant-put-flesh-on-bones-of-3bn-rd-deal/

News/ News/ R&D

Sumitomo Dainippon bolts on pipeline via $3bn Roivant alliance

Phil Taylor M&A, Roivant, Sumitomo Dainippon Pharma 0 Comment

Vivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs

Sumitomo Dainippon bolts on pipeline via $3bn Roivant alliance

https://pharmaphorum.com/news/sumitomo-dainippon-bolts-on-pipeline-via-3bn-roivant-alliance/

News

Roivant wins $200m backing to expand R&D operations

Richard Staines R&D, Roivant 0 Comment

Biotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the

Roivant wins $200m backing to expand R&D operations

https://pharmaphorum.com/news/roivant-wins-200m-backing-to-expand-rd-operations/

Market Access/ News/ News/ R&D

Ramaswamy’s Roivant signs diabetes drug deal with Poxel

Richard Staines Diabetes, Poxel, R&D, Roivant 0 Comment

Biotech entrepreneur hopes to bounce back from Alzheimer’s disappointment

Ramaswamy’s Roivant signs diabetes drug deal with Poxel

https://pharmaphorum.com/news/ramaswamys-roivant-signs-diabetes-drug-deal-poxel/

Market Access/ News/ News/ News/ R&D/ R&D/ Top stories

Axovant CEO David Hung quits after Alzheimer’s drug failure

Richard Staines Alzheimer's, Axovant, neurology, R&D, Roivant 0 Comment

Last month the biotech Axovant was rocked by the failure of its star drug intepirdine in Alzheimer’s disease – and the fall-out is still being felt, with CEO David Hung deciding to walk out.

Axovant CEO David Hung quits after Alzheimer’s drug failure

https://pharmaphorum.com/news/axovant-ceo-hung-quits-alzheimers-drug-failure/

Trending

Roivant

Login